Heparin Sodium is formed by a heterogeneous group of straight-chain anionic mucopolysaccharides called glycosaminoglycan. It can be described as a glycosaminoglycan sulfate. Heparin delays the coagulation of fresh blood. Heparin is strongly acidic because of its content of covalently linked sulfate and carboxylic acid groups. In heparin sodium, the acidic protons of the sulfate units are partially replaced by sodiumions.
The mechanism of action is complex, mainly through binding to antithrombin III (AT-III), which enhances the latter\'s inhibition of activated coagulation factors II, IX, X, D and Ⅻ, the consequences of which involve preventing platelet agglutination and destruction, preventing the formation of thrombin-activating enzymes, preventing the conversion of prothrombin into thrombin, and inhibiting thrombin, thereby preventing the conversion of fibrinogen into fibrin, thus exerting an anticoagulant effect. Heparin sodium is available in two more common forms, oral preparations and injectable solutions. The injectable solution is a sterile preparation of sodium heparin extracted from porcine intestinal tissue, which is injected in water when used and has standardised anticoagulant activity.
Venous thromboembolism (VTE) is a condition in which a blood clot forms most often in the deep veins of the leg, groin or arm (known as deep vein thrombosis, DVT) and travels in the circulation, lodging in the lungs (known as pulmonary embolism, PE). Anticoagulant therapy with heparin drugs can prevent further expansion of thrombus and dissolve the thrombus that has been formed by endogenous plasmin, thereby reducing the mortality and recurrence rate of PE. Some women who are pregnant will experience complications that can involve their health, their baby’s health, or both. Sometimes, diseases or conditions the mother had before she become pregnant can lead to complications during pregnancy. Some complications occur during delivery. During pregnancy, pregnant women can inject low molecularweight heparin sodium to prevent complications during pregnancy. Atrial fibrillation increases stroke risk and adversely affects cardiovascular haemodynamics, so that people need a long-term Heparin Sodium therapy.
Get the complete sample, please click:https://www.globalmarketmonitor.com/reports/610633-heparin-sodium-market-report.html
Heparin Sodium Industry Market Analysis Forecast
After a period of development, the industry is at a mature stage. According to our research, the Global Heparin Sodium market has a total revenue of 3930.78 M USD back in 2015, and decreased to 3786.27 M USD in 2019. We made a series of functional calculation and deduced the past 6 year’s data with scientific model. Finally, we made the prediction that the value of Heparin Sodium markets can be 5153.29 M USD by 2025. The CAGR of Heparin Sodium is 5.27% from 2019 to 2025.
With the continuous upgrading of products and the development of technology and economy, the market continues to expand. Europe was the largest revenue market with a market share of 72.27% in 2015 and 63.82% in 2019, an increase of -8.45%. In 2019, the North America market share was 19.42%, ranking second. In addition, China Heparin Sodium market is expected to be the growing market. Development of economy, increase downstream demand, technology innovation progress in these areas will promote the Heparin Sodium market. Heparin Sodium companies are mainly from Europe; the industry concentrate rate is moderate. The top three companies are Sanofi, Novartis, LEO Pharma with the revenue market share of 42.35%, 8.73% and 8.53% in 2019.
The growth of the Heparin Sodium market is driven by the downstream demand market. As the global economy develops, the population continues to increase. Growing market demand plays an active role in the expansion of the Heparin Sodium market. Higher product quality and more affordable products will be one of the growth opportunities in this market in the future. At the same time, competition in new regions may become more intense. This may become a factor hindering market growth.
Influence of COVID-19 Outbreak on Heparin Sodium Industry Development
COVID-19 can lead to the risk of thrombosis. The current US authority recommends the use of low molecular weight heparin for prevention and treatment，which increases the demand for low molecular weight heparin. Clinical trials for the treatment of COVID-19 patients in many countries have found that multiple COVID-19 patients have concurrent venous thromboembolism (VTI), especially with pulmonary embolism PE), which may cause the infection to worsen, And even an important cause of death.
In addition, some patients have obvious hypercoagulability in the early stage, and extensive micro thrombosis may be secondary to them without intervention. Because the medical community in many countries and regions has issued guidelines for the application of low-molecular-weight liver blood tests for prevention. The American Society of Hematology (ASH) and the International Society of Thrombosis and Hemostasis (ISTH) both recommend that the COVID-19 patients should receive low-molecular-weight heparin sodium injections to prevent thrombosis if there are no contraindications.
After the epidemic is over, the people will have higher demand for health management and health care, which will promote the growth of medical consumption expenditure. Driven by this factor, more new entrants will enter the pharmaceutical industry, which will promote the research of drugs and reagents in the pharmaceutical industry. The most important consumer market for heparin sodium is still the European and American markets, and the European and American regions have not completely gotten rid of COVID-19. The epidemic prevention and control measures will still affect the flow of people and activities, and then affect the logistics, making the production of pharmaceutical manufacturing such as heparin sodium suffer due to the supply of raw materials and labor shortages. Although the government has issued many policies to promote the coordinated resumption of work and production in all links of the industrial chain, for the time being, most companies and markets have not been able to fully recover to their pre-epidemic status.
Get the complete sample, please click:https://www.globalmarketmonitor.com/reports/610633-heparin-sodium-market-report.html
We provide more professional and intelligent market reports to complement your business decisions.
Chinese